LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows
LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreFri, 30th Oct 2020 09:21
LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows
Read moreNovartis buys UK gene therapy firm Gyroscope for up to USD1.5 billion
Read more(Sharecast News) - Syncona on Wednesday said it had sold its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5bn (£1.1bn) on a cash and debt free basis.
Read moreSyncona portfolio firm Freeline cuts workforce and narrows focus
Read moreSyncona invests GBP19 million in Quell Therapeutics via funding round
Read moreEXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan
Read moreIN BRIEF: Syncona net assets drop as Life Science portfolio takes hit
Read more(Sharecast News) - Healthcare investor Syncona reported net assets of £1.15bn at the end of its first half on Thursday, or 171.7p per share, down from £1.3bn or 193.8p per share at the end of March.
Read moreSyncona's Freeline loss widens but progresses on Fabry's disease drug
Read more(Sharecast News) - Healthcare company Syncona announced new data from its portfolio company Freeline Therapeutics' ongoing phase 1 and 2 'MARVEL-1' dose-finding clinical trial of 'FLT190' for the treatment of Fabry disease on Wednesday, with the second patient dosed generating "encouraging" data.
Read moreTRADING UPDATES: Sealand's China progress; Altus finds gold
Read moreSyncona's Autolus gets USD250 million investment from Blackstone
Read moreUK earnings, trading statements calendar - next 7 days
Read moreTRADING UPDATES: BATM signs new deal; Synectics wins two projects
Read moreSyncona focuses on portfolio as net asset value drops in first quarter
Read more